Home » Newsletters » BioWorld Science

BioWorld Science

July 24, 2013

View Archived Issues

ASP-1017FM has potentially beneficial effects on migraine

Hanmi Science discloses new protein kinase inhibitors for cancer

Pulmatrix commences phase Ib COPD study

Novel agents for metabolic diseases disclosed by Cadila Healthcare

Genmab submits IND to conduct phase I study of HuMax-TF-ADC

Gilead Sciences presents novel agents for HIV infection

Researchers at Rutgers disclose new antibacterial RNA polymerase inhibitors

Daiichi Sankyo and Ube Industries synthesize new CETP inhibitors

Experiments profile preclinical activity of Alzheimer's disease candidate AZD-3293

Novel drug and drug target for the treatment of addictive disorders characterized

Noven Pharmaceuticals reports topline results from phase II d-ATS

Results of a phase I evaluation of antigen-specific tolerance for multiple sclerosis

Ligand signs license agreement with Azure Biotech for lasofoxifene

New biomaterial coatings to improve bone-bioimplant interface stability

Cellular Biomedicine begins phase I trial of adipose-derived mesenchymal progenitor cells

Johnson & Johnson reviews second quarter 2013

Aquinox begins dosing in phase II trial of AQX-1125 in BPS/IC

Protalex continues enrollment in phase Ib trial of PRTX-100 following third interim review

Mast Therapeutics' QT study of MST-188 meets primary endpoint

Charleston Laboratories completes pre-IND meeting regarding migraine treatment

Phase III trial comparing obinutuzumab to Rituxan in CLL meets primary endpoint

Arrowhead commences phase I trial of RNAi therapeutic

Quest PharmaTech and AD Biotech form joint venture

Trovagene's reports validation of assay for detecting BRAF mutation in urine

Roche launches new drug monitoring tests for immunosuppressive therapies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...